As for drug therapy for patients with T2DM, metformin still remains the first-line therapy choice, for its excellent role in reducing hepatic glucose output, enhancing insulin sensitivity and lowering HbA1c by about 1–2% (4). This evidence concerns the gene INS and type 2 diabetes mellitus.